Pharmaceuticals Acquisitions in Pennsylvania

Mallinckrodt plc and Endo, Inc. have completed a business combination to create a global, scaled therapeutics company, with Endo shareholders receiving cash and a 49.9% pro forma equity stake. The combined company will operate branded therapeutics and a generics/sterile injectables business (to be named Par Health), with Par Health intended to be spun off as an independent company targeted for Q4 2025 to unlock focused growth and realize synergies.

Paratek Pharmaceuticals has completed its acquisition of Optinose, acquiring all outstanding shares for approximately $330 million including debt and contingent value rights. The deal, financed with capital from Paratek, B-FLEXION Life Sciences and Novo Holdings and debt financing from Oaktree, adds Optinose’s XHANCE product to Paratek’s specialty therapeutics portfolio.

Cooper Consumer Health has completed the acquisition of the Over-the-Counter (OTC) business of Viatris Inc., following regulatory approvals and worker council consultations. The deal brings more than 200 brands (including Betadine, Saugella, Armolipid and CB12), two manufacturing sites in Mérignac (France) and Confienza (Italy) and an R&D centre in Monza (Italy) into Cooper's platform, doubling Cooper's revenues to approximately €1.2bn.

Harmony Biosciences Holdings, Inc. agreed to acquire Zynerba Pharmaceuticals, Inc. in a cash tender offer of $1.1059 per share (approximately $60 million) plus one contingent value right (CVR) per share for up to $140 million of milestone-based payments (total potential consideration up to $200 million). The transaction, unanimously approved by both boards, is expected to close in Q4 2023 and will add Zynerba’s synthetic transdermal cannabidiol candidate Zygel and related rare neuropsychiatric programs to Harmony’s pipeline.

BroadOak Capital Partners led an investor-backed launch of Microsize after acquiring Lonza’s North American micronization business in Quakertown, Pennsylvania. The newly independent CDMO — operating three facilities and focused on micronization and particle-size control for APIs and excipients — will be run by industry veterans including Chairman Derek Hennecke and CEO TJ Higley to expand US-based API solubility and bioavailability enhancement capabilities.

Altaris Capital Partners completed the acquisition of Veranova (formerly Johnson Matthey's Health business) from Johnson Matthey PLC for total consideration of up to £325 million, with Johnson Matthey retaining approximately a 30% equity stake. Veranova is a global CDMO focused on specialty and complex active pharmaceutical ingredients (APIs), headquartered in Wayne, Pennsylvania, with roughly 900 employees across seven development and manufacturing sites in North America, Europe and Asia.

Consegna Pharma Inc. has acquired Fathom Pharma LLC, making Fathom a wholly owned subsidiary to strengthen Consegna's long-acting injectable (LAI) portfolio and initiatives addressing the opioid crisis. The acquisition is intended to accelerate clinical development of long-acting pain therapeutics that are designed to be less susceptible to abuse or diversion.

Adare Pharma Solutions, a PE-backed contract development and manufacturing organization (CDMO), has acquired Frontida BioPharm, a vertically integrated CDMO focused on oral formulations. The deal expands Adare’s capabilities—including high-potency compound handling and packaging services—and increases its manufacturing footprint; Adare is backed by Thomas H. Lee Partners and Frazier Healthcare Partners.

PMC Group International, Inc. announced the acquisition of Cobra Investments Management Inc. and its two subsidiaries, Copperhead Chemical Company Inc. and Copperhead Investments Inc., effective February 5, 2021. Copperhead, headquartered in Tamaqua, Pennsylvania, is a long-established manufacturer of pharmaceutical-grade nitroglycerin and energetic chemicals for defense; PMC said the deal strengthens its pharmaceutical manufacturing capabilities and creates synergies with its global pharma and specialty-chemicals businesses.

Charterhouse Capital Partners–backed Laboratoires SERB has agreed to acquire BTG Specialty Pharmaceuticals from Boston Scientific. The deal expands SERB’s portfolio of emergency and critical‑care medicines (including CroFab, DigiFab and Voraxaze), strengthening its manufacturing capabilities and global commercial reach.

Thomas H. Lee Partners and Frazier Healthcare Partners have acquired Adare Pharmaceuticals (to be rebranded Adare Pharma Solutions) from TPG Capital. The deal includes Adare’s CDMO, pharmaceutical technology and microbiome businesses while TPG retained rights to an EoE product spun into a separate entity; terms were not disclosed.

Pace Analytical Services, LLC acquired Emerson Resources, Inc., a CDMO specializing in solid oral dosage development and cGMP clinical trial material manufacturing. The acquisition expands Pace Life Sciences' capabilities to include clinical trial material production and transitions Emerson's Norristown, Pennsylvania lab into the Pace Analytical network while Emerson principals exit the business.

Altasciences, a mid-size contract research organization based in Laval, Quebec, has acquired Alliance Contract Pharma to add small-molecule contract manufacturing and analytical services, including commercial manufacturing, GMP warehouse storage, and clinical supply distribution. The acquisition expands Altasciences' integrated early‑phase drug development offering by adding manufacturing and analytical capabilities to its preclinical, clinical, and bioanalytical services.